Cellectis Reports Q3 2026 Results; Announces Strategic Pivot to In Vivo Gene Editing
Cellectis S.A. reported a net loss of $101.1 million for the nine-month period ended September 30, 2026, compared to a net loss of $41.3 million in the prior-year period, as revenues declined 76% to $14.8 million driven by lower activity under the AstraZeneca collaboration. The company announced a strategic transformation to become an in vivo gene editing company focused on chronic diseases, exiting development of lasme-cel and eti-cel while advancing.HEAL-101 and.HEAL-201 programs. The company recognized $26.8...
Key takeaways
Strategic pivot: Company announced transition to in vivo gene editing company focused on developing treatments for chronic diseases, exiting lasme-cel and eti-cel programs while seeking strategic partnering opportunities.
New pipeline programs: .HEAL-101 targets APOC3 for severe hypertriglyceridemia with Phase 1 IIT in China planned (data expected H2 2027); .HEAL-201 targets PCSK9 for severe hypercholesterolemia with Phase 1 IIT planned (data expected H1 2028).
Restructuring charges: $34.9 million impact from strategic transformation including $26.6 million impairment on Raleigh and Paris facilities, $6.2 million in termination benefits, and $2.1 million in program close-out costs.
Financial guarantee exposure: $9.4 million ECL allowance recognized on lease guaranty for Cibus (formerly Calyxt) Roseville, Minnesota facility following landlord complaint; total potential undiscounted exposure of $18.8 million.
Cash position: $28.2 million in cash and cash equivalents plus $118.3 million in fixed-term deposits as of September 30, 2026; company expects sufficient funds into H2 2028 after restructuring.
AstraZeneca collaboration: $14.0 million revenue recognized from AZ JRCA in Q3 2026; milestone structure amended to up to $253 million per product candidate (up from $220 million).
Key metrics
Customer concentration
Disclosure changes
- Strategic transformation
Company announced strategic pivot to become an in vivo gene editing company focused on developing long-lasting treatments for chronic diseases, exiting development of lasme-cel and eti-cel while seeking strategic partnering opportunities. The realignment will reduce global headcount by up to 70% from pre-transition levels over 2026-2027.
Fundamental shift in business strategy and pipeline priorities; significant restructuring charges; extended cash runway - Impairment testing and asset impairments
Company recognized $26.8 million impairment loss on right-of-use assets ($2.1 million) and property, plant and equipment ($24.8 million) related to Raleigh and Paris facilities following strategic transformation and changes in expected use of assets.
Significant non-cash charge reflecting reduced asset values due to strategic pivot and exit from cell therapy manufacturing - Financial guarantee and expected credit loss
Company recognized $9.4 million expected credit loss allowance on financial guarantee for Cibus (formerly Calyxt) Roseville, Minnesota lease following September 2026 landlord complaint seeking recovery of alleged defaults under lease and guaranty; total potential undiscounted exposure of $18.8 million.
Material contingent liability related to former Calyxt subsidiary; ongoing litigation with landlord - Restructuring provisions
Company recognized $6.1 million in termination benefits provisions for restructuring plan in U.S. and France, $1.0 million for lasme-cel and eti-cel program close-out activities, and $0.9 million for leased premises restoration costs.
Significant restructuring charges associated with strategic transformation and workforce reduction - AstraZeneca collaboration milestone structure
On November 17, 2025, AZ Ireland and Cellectis amended the JRCA to prospectively change milestone payment structure to up to $253 million per product candidate (up from up to $220 million previously) for each of up to 10 candidate products.
Increased potential milestone value from AstraZeneca collaboration; reflects enhanced partnership terms - EIB warrant fair value changes
Fair value gain of $15.1 million on Tranche A, B, and C warrants issued to European Investment Bank recognized in nine months ended September 30, 2026, compared to $5.8 million fair value loss in prior year period.
Significant non-cash fair value adjustment on derivative instruments; reflects changes in company share price and volatility assumptions
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow CLLS in real time
Get material earnings, filing, IR, and earnings-call alerts by email.